BRCA2 and breast cancer: The PARP inhibitor, AZD2281 (Olaparib) given to patients with BRCA1- and/or BRCA2-deficient advanced breast cancer (of which >50% were triple-negative) in a single arm study resulted in an overall response rate of 41% and progression free survival of about six months [13].